I agree that this site is using cookies. You can find further informations here.
X
Mato, A. R.
1957  results:
Search for persons X
?
1

Potential threat of arsenic contamination of water sources ..:

, In: Environmental Arsenic in a Changing World,
Mato, R.R.A.M. ; Kassenga, G.R. - p. 163-168 , 2019
Link: https://doi.org/10.1201/..
 
?
2

Concrete block production from construction and demolition ..:

Sabai, M.M. ; Cox, M.G.D.M. ; Mato, R.R...
Resources, Conservation and Recycling.  72 (2013)  - p. 9-19 , 2013
Link: https://doi.org/10.1016/..
 
?
3

Environmental implications involving the establishment of s..:

Mato, R.R.A.M.
Resources, Conservation and Recycling.  25 (1999)  1 - p. 1-16 , 1999
Link: https://doi.org/10.1016/..
 
?
4

Critical review of industrial and medical waste practices i..:

Mato, R.R.A.M ; Kaseva, M.E
Resources, Conservation and Recycling.  25 (1999)  3-4 - p. 271-287 , 1999
Link: https://doi.org/10.1016/..
 
?
5

A study on problems of management of medical solid wastes i..:

Mato, R.R.A.M ; Kassenga, G.R
Resources, Conservation and Recycling.  21 (1997)  1 - p. 1-16 , 1997
Link: https://doi.org/10.1016/..
 
?
6

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Patel, K. ; Brown, J. R. ; Desikan, S. P....
Hematological Oncology.  41 (2023)  S2 - p. 185-187 , 2023
Link: https://doi.org/10.1002/..
 
?
7

P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SE..:

Jurczak, W. ; Alencar, A. J. ; Guru Murthy, G. S....
HemaSphere.  6 (2022)  - p. 579-580 , 2022
Link: https://doi.org/10.1097/..
 
?
8

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STU..:

Mato, A. R. ; Wierda, W. G. ; Pagel, J. M....
HemaSphere.  6 (2022)  - p. 1743-1744 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P639: OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEM..:

Mato, A. R. ; Chen, Y. ; Girvan, A. C....
HemaSphere.  6 (2022)  - p. 537-538 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Roeker, L. E. ; Mato, A. R. ; Brown, J. R....
HemaSphere.  6 (2022)  - p. 538-539 , 2022
Link: https://doi.org/10.1097/..
 
?
11

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 48-49 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL..:

Mato, A. R. ; Manzoor, B. S. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 569-570 , 2022
Link: https://doi.org/10.1097/..
 
?
13

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I..:

Barrientos, J. C. ; Barr, P. M. ; Mato, A. R....
HemaSphere.  6 (2022)  - p. 1758-1759 , 2022
Link: https://doi.org/10.1097/..
 
?
14

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STU..:

Sharman, J. P. ; Jurczak, W. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 1744-1745 , 2022
Link: https://doi.org/10.1097/..
 
?
15

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIV..:

Jurczak, W. ; Shah, N. N. ; Lamanna, N....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
1-15